Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $44.65 USD
Change Today -0.08 / -0.18%
Volume 724.3K
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NUVA) Snapshot

Open
$44.94
Previous Close
$44.73
Day High
$45.55
Day Low
$44.27
52 Week High
01/8/15 - $51.23
52 Week Low
05/21/14 - $31.71
Market Cap
2.2B
Average Volume 10 Days
761.3K
EPS TTM
$0.42
Shares Outstanding
48.4M
EX-Date
--
P/E TM
107.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NUVA)

nuvasive inc (NUVA) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NUVA) Details

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product is Maximum Access Surgery (MAS), a minimally-disruptive surgical platform that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing process consist of Osteocel Plus and Osteocel Pro allograft (donated human tissue), which are cellular matrix products containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during non-spine. The company sells its products through independent sales agencies, directly-employed sales shareowners to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,500 Employees
Last Reported Date: 02/25/15
Founded in 1997

nuvasive inc (NUVA) Top Compensated Officers

President and Chief Operating Officer
Total Annual Compensation: $545.7K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $380.5K
President of US Sales and Services
Total Annual Compensation: $375.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $454.1K
Consultant
Total Annual Compensation: $900.0K
Compensation as of Fiscal Year 2014.

nuvasive inc (NUVA) Key Developments

NuVasive, Inc. Reaches Agreement in Principle with the U.S. Department of Justice to Settle OIG Matter

NuVasive, Inc. announced that it has reached an agreement in principle with the U.S. Department of Justice (DOJ) related to the previously disclosed subpoena issued to the Company in 2013 by the Office of Inspector General of the Department of Health and Human Services (OIG). Subject to completion of a definitive written settlement agreement, the company has agreed to pay $13.8 million, including fees, to the United States to resolve this matter. The company does not currently anticipate entering into a corporate integrity agreement with the OIG as part of the settlement. Finalizing the written settlement agreement could take several months.

NuVasive Provides Revenue Guidance for the First Quarter of 2015 and Earnings Guidance for the Year 2015

NuVasive provided revenue guidance for the first quarter of 2015. For the quarter, the company anticipated revenue will be in excess of $190 million, including more than $2 million of currency headwinds. The company also announced it remains on track for its 2015 profitability goals.

NuVasive, Inc. Announces Management Changes

On March 28, 2015, Mr. Alex V. Lukianov, the Chief Executive Officer and the Chairman of the Board of the NuVasive, Inc. and a member of its Board of Directors, resigned as Chairman, Chief Executive Officer, and as a member of the Board and all other positions he had with the Company subsidiaries and affiliates, effective March 27, 2015. Mr. Lukianov will remain with the Company as a consultant to assist with the transition and serve as a special advisor to the successor Chief Executive Officer through September 30, 2016. Also effective on March 27, 2015, the Board appointed Mr. Gregory T. Lucier to serve as the Company’s interim Chief Executive Officer and Chairman of the Board. In connection with such appointment, Mr. Lucier resigned from his seats on the Board of Director’s Audit and Compensation Committees. Mr. Lucier, age 50, has served as member of Board since December 2013. Mr. Lucier has over 25 years of executive management experience and served as Chairman of the Board and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until their acquisition by Thermo Fisher Scientific, Inc. in February 2014. Prior to joining Life Technologies, Mr. Lucier served as Chief Executive Officer and President at GE Medical Systems Information Technologies, Vice President for Global Services at GE Medical Systems and served as a corporate officer of the General Electric Corporation. He currently serves as board chairman for the Sanford-Burnham Medical Research Institute, and previously served on the Board of CareFusion Corporation until the completion of its acquisition by Becton Dickinson on March 17, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUVA:US $44.65 USD -0.08

NUVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $50.16 USD -0.07
Globus Medical Inc $23.30 USD -0.59
Integra LifeSciences Holdings Corp $65.48 USD +6.70
Masimo Corp $34.17 USD +0.41
Thoratec Corp $40.14 USD +0.03
View Industry Companies
 

Industry Analysis

NUVA

Industry Average

Valuation NUVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.